Internal Med

Your Article Summary

See Latest Articles

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
The Lancet - Early Online Publication, 06/09/09

Home PD et al. – Addition of rosiglitazone to glucose-lowering therapy in pts with type 2 diabetes is confirmed to increase risk of heart failure and of some fractures, mainly in women. Despite inconclusive data are about any possible effect on myocardial infarction, rosiglitazone does not increase risk of overall cardiovascular morbidity or mortality compared with standard glucose-lowering drugs.

• Study of cardiovascular outcomes after addition of rosiglitazone to either metformin or sulfonylurea vs combination over 5—7 yr follow-up
• Assessment of comparative safety
• Multicentre, open-label trial of 4447 pts with type 2 diabetes on metformin or sulfonylurea monotherapy with mean hemoglobin A1c (HbA1c) of 7.9%
• Randomization to addition of rosiglitazone (n=2220) or combination of metformin and sulfonylurea (active control group, n=2227)
• Primary endpoint: cardiovascular hospitalization or cardiovascular death

• 321 pts in rosiglitazone group and 323 in active control group experienced primary outcome during mean 5.5-yr follow-up, meeting criterion of non-inferiority
• HR was 0.84 for cardiovascular death, 1.14 for myocardial infarction, and 0.72 for stroke
• Heart failure causing admission to hospital or death in 61 people in rosiglitazone group and 29 in active control group
• Upper and distal lower limb fracture rates increased mainly in women assigned to rosiglitazone
• Mean HbA1c lower in rosiglitazone vs control group at 5 yrs

Related Articles

See all related articles

Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin over Four-Years in Spite of Greater Weight Gain: Observations from ADOPT (A Diabetes Outcome Progression Trial)
Diabetes Care, 10/14/09    Relevance Score: 88%

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial
Hepatology, 11/02/09    Relevance Score: 87%

Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus
Metabolism-Clinical and Experimental, 10/26/09    Relevance Score: 87%

Effects of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, on the Pharmacokinetics of Rosiglitazone
Cardiovascular Drug Reviews, 11/17/09    Relevance Score: 85%

Stretch Reduces Nephrin Expression via an Angiotensin II-AT1-dependent Mechanism in Human Podocytes: Effect of Rosiglitazone
American Journal of Physiology: Renal Physiology, 11/17/09    Relevance Score: 85%

Today in Cardiology...keeping you current

Receive free subspecialty "5-minute updates" via email

Trends in hypertension treatment in diabetes
Current Hypertension Reports, 12/09/09

Electrocardiogram QT Interval Increases in Acute Stroke
Cerebrovascular Diseases, 12/09/09

Relation of Urotensin II Levels to Lone Atrial Fibrillation
The American Journal of Cardiology, 12/09/09

 See all of Cardiology

Today in Clinical Pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study
Diagnostic Microbiology and Infectious Disease, 12/09/09

Avian influenza – A review for doctors in travel medicine
Travel Medicine and Infectious Disease , 12/09/09

Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: A double-blind, randomised trial
The Lancet Oncology - Online First, 12/09/09

 See all of Clinical Pharmacology

Today in Vascular Medicine...keeping you current

Receive free subspecialty "5-minute updates" via email

Metabolic Risk Factors Among Medicaid Outpatients With Schizophrenia Receiving Second-Generation Antipsychotics
Psychiatric Services, 12/09/09

Coronary Calcification in Patients with Chronic Kidney Disease and Coronary Artery Disease
Clinical Journal of the American Society of Nephrology, 12/09/09

Outcomes Among Hypertensive Patients With Concomitant Peripheral and Coronary Artery Disease. Findings From the INternational VErapamil-SR/Trandolapril STudy
Hypertension, 12/08/09

 See all of Vascular Medicine